723 related articles for article (PubMed ID: 29079968)
1. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
Min JS; Bae SK
Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
[TBL] [Abstract][Full Text] [Related]
2. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Duan P; Zhao P; Zhang L
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
[TBL] [Abstract][Full Text] [Related]
5. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
[TBL] [Abstract][Full Text] [Related]
7. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
8. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
[TBL] [Abstract][Full Text] [Related]
10. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
[TBL] [Abstract][Full Text] [Related]
12. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
13. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
[TBL] [Abstract][Full Text] [Related]
16. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
18. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]